 BRENTWOOD, Tenn, March 01, 2021 GLOBE NEWSWIRE -- IMAC Holdings, Inc. Nasdaq: IMAC IMAC or the Company, today announces it has completed the first cohort of its Phase 1 clinical trial for its investigational compound utilizing umbilical cord-derived allogenic mesenchymal stem cells for the treatment of bradykinesia due to Parkinsons disease. 